



Neuren (NEU) - ASX Announcement

1 July 2020

Electing to receive SPP documents by e-mail

On 29 June 2020 Neuren announced that it would offer participation in a Share Purchase Plan (SPP) to shareholders in Australia and New Zealand at the record date of Friday 26 June 2020. The SPP is due to open on Thursday 9 July 2020. **Given the potential for delays to postage due to Covid-19, Neuren would like to encourage shareholders who currently receive investor communications by mail to elect before 5.00 pm AEST on Sunday 5 July 2020 to receive investor communications via e-mail.** This should enable more timely receipt of the SPP offer documents and instructions. The election can be made on the share registry website by following the instructions below:

1. Go to the share registry website at www.linkmarketservices.com.au.
2. Select **'Investor Login'**
3. Click on the **'Single Holding'** section (unless you have set up a **'Portfolio'**, in which case you will need to enter your email and Password);
4. At **'Issuer Name'** enter **'NEU'** or **'Neuren Pharmaceuticals Limited'**
5. Enter your HIN or SRN
6. Enter the postcode (or Country Code if outside Australia) relevant to each shareholding
7. Enter the security code as displayed
8. Read and agree to the terms and conditions by selecting the tick box
9. Select **'Holdings'** from the top menu bar
10. Select **'Holding Details'**
11. Select **'Communications'**
12. Select **'All communications electronically'** and enter your e-mail address in the **'E-mail sent to:'** box
13. Select **'Next'** and then select **'Confirm'**

About Neuren

Neuren is developing new therapies for neurodevelopmental disorders with high unmet need, utilizing synthetic analogs of neurotrophic peptides that occur naturally in the brain. Trofinetide is currently in a Phase 3 clinical trial for Rett syndrome and has completed a Phase 2 clinical trial in Fragile X syndrome. The programs have each received Fast Track designation by the US Food and Drug Administration and Orphan Drug designation in both the United States and the European Union. Neuren has granted an



exclusive license to ACADIA Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, whilst retaining all rights outside North America. Neuren is advancing the development of NNZ-2591 for Phelan-McDermid, Angelman and Pitt Hopkins syndromes, each of which has received Orphan Drug designation in the United States.

Contact:

Jon Pilcher, CEO

jpilcher@neurenpharma.com; +61 438 422 271

ASX Listing Rules information

This announcement was authorized to be given to the ASX by the Company Secretary of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.